Watch Fireside Chat Below, or Click HERE: IPO Edge hosted a fireside chat with West Point Gold Corp. (TSX: WPG) (OTC: WPGCF) Chief Executive Officer Derek Macpherson, moderated by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large Jarrett Banks in a video session...

Watch Video Highlights Below, or Click HERE:  Tech Edge hosted a fireside chat on June 9 at Pax8 Beyond 2026 in Salt Lake City with Chance Weaver, Vice President of AI Adoption at Pax8. The in-person interview was joined by Editor-in-Chief...

By Karen Roman Fortitude Mining Holdings, Inc., a Zcash mining platform, has agreed to merge with HeartSciences Inc. (Nasdaq: HSCS) in an all-stock transaction that will take the company public. The combined company is expected to trade on the Nasdaq under...

Watch Video Highlights Below, or Click HERE:  Tech Edge hosted a fireside chat on June 9 at Pax8 Beyond 2026 in Salt Lake City with Libby McIlhany, Chief Product Officer and Craig Donovan,  Chief Operating Officer, at Pax8. The in-person interview was joined by Editor-in-Chief...

Watch Video Highlights Below, or Click HERE:  Tech Edge hosted a fireside chat on June 7 at Pax8 Beyond 2026 in Salt Lake City with Nick Heddy, President and Chief Commerce Officer at Pax8. The in-person interview was joined by Editor-in-Chief...

Download the Complete Report Here Local Bounti Corporation (LOCL) From Capacity Ramp to Yield-Led Growth: Stack & Flow, Retail Demand, and SKU Breadth Support LOCL’s Next Phase LOCL is a branded CEA fresh-produce platform built around patented Stack & Flow...

By Karen Roman Prolium Bioscience, Inc. said it dosed its first patient in Phase 1/2 study of PRO-203, a T-cell engager treatment for systemic sclerosis, following the completion of a study in 20 healthy volunteers. The company also completed the...

By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) reported in vitro proof-of-concept data validating its BiTAC-ADC platform for cancer therapies, with selective tumor cell killing while sparing healthy cells. The company will showcase partnering opportunities for its platform at the...

By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it nominated ACU301 and ACU401, two candidates in its Enhanced Brain Delivery program, to treat Alzheimer’s Disease. The nomination comes after the company exercised its option with JCR Pharmaceuticals as part...